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BACKGROUND
In pediatric ages, sublingual immunotherapy (SLIT) allows allergic
children to approach the inhaling desensitizing therapy. However,
SLIT causes quite a few compliance problems and sometimes it is dif-
ficult to carry it out for the required long term. The alternative is sub-
cutaneous immunotherapy (SCIT), commonly performed with a
syringe. This technique hasn’t changed much in time and it is not
without risks or discomfort. This has led to the search for alternative
ways of vaccine administration, in order to reduce discomfort to chil-
dren by improving compliance and diminishing the potential risks of
adverse reactions.
OBJECTIVE
The study aimed to assess the patient’s perceived pain and the safety
of a new way of administration of SCIT, with a needleless device.
METHODS
Children with grass or mite-induced allergic rhinoconjunctivitis and/
or bronchial asthma were prescribed a glutaraldehyde-polymerized
allergenic extract (Allergovac Polymeryzed®, Bial Aristegui, Italy). Each
dose was divided in two parts: half injected with the traditional syr-
inge (dose A), half in the other arm with a needleless device (Injex,
Greytree, Ross on Wye, UK; dose B). Patients were blindfolded. The
perceived pain and the difficulties of the procedure were registered
on a dedicated VAS scale immediately (time 1) and 20 minutes after
the first injection (time 20). Also, we evaluated the occurrence of oc-
casional adverse events during such procedure and we assessed the
perceived difficulty by the doctor administering with such method.
RESULTS
39 patients, aged 5-18 years, were recruited and assessed. All patients
completed the study, which involved 468 grass pollen AIT SCIT doses,
of which 234 with needleless device. At time 1, the use of the needle-
less device led to an 88% reduction of the pain perception average rate
(from 16,8 to 1,97). The difficulty for the technician to make the inocu-
lum was also analyzed (expressed by an increasing rate, from 0 to 4). In
all 6 doses, for each child, the difficulty rate 2 relates to an almost con-
stant number of patients, while the highest difficulty rates (grade 3 and
grade 4) gradually decrease (until they disappear).© The Author(s). 2017 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeCONCLUSIONS
The vaccine administration with needleless device has various advan-
tages and it ensures a better acceptance in comparison with admin-
istration by traditional SCIT. This is important in order to start the
immunotherapy at an early stage, as it is recommended by the most
recent studies, so that the natural evolution of the allergic disease
can be immediately modified. The new technique ensures a higher
safety both for the vaccinator and for the patient, with a better ac-
ceptance of the procedure by the patient and therefore a better and
wider compliance to the vaccination schedules.
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BACKGROUND
Cow’s milk protein allergy (CMPA) affects from 0.6 to 0.9% of the gen-
eral population, being a public health problem that mainly affects the
pediatric population. The current treatment of CMPA involves the total
elimination of the intake of this protein. Whenever a diet free of cow’s
milk protein is prescribed, it must be nutritionally adequate. After the
first year of life, camel milk has been proposed as an alternative to be
ingested by patients suffering from CMPA by virtue of the difference in
amino acid sequence with the cow’s milk protein, in addition it has a
low amount of β-casein (Bos d8) and absence of β-lactoglobulin (Bos
d5), as well as an adequate nutritional balance with components such
as lactoferrin, immunoglobulins, lysozyme and vitamin C.
OBJECTIVE
To evaluate the safety of camel milk administration in patients with
CMPA using double blind placebo controlled oral food challenge
(DBPCOFC) methodology.
METHODS
A placebo-controlled, double-blind clinical trial was performed at the
Hospital Infantil de México Federico Gómez (HIMFG). Inclusion was
made in patients aged from 1 to 18 years with suspicion of CMPA,
and a DBPCOFC to cow milk was performed to establish diagnosis.
Only those in which the disease was corroborated by this method
were randomized into to 2 groups:
 Administration of camel milk or
 Administration of amino acid formulale is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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and the opposite challenge was performed previous 6 weeks of
awaiting.
RESULTS
We included 49 patients with suspected cow’s milk protein allergy,
and the diagnosis was established in 15 patients by DBPCOFC. None
of them had adverse effects after the administration of camel milk
during the oral challenge and 2 weeks later after daily intake.
CONCLUSIONS
This study demonstrates that camel milk is safe and adequately toler-
ated in patients older than 1 year old with CMPA and could be con-
sidered as an alternative, given the benefit of better taste, nutritional
efficiency and possibly lower cost than other formulas.
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BACKGROUND
Anaphylaxis is an acute though potentially life-threatening multisys-
tem allergic reaction characterized by a rapid inception and progres-
sion following exposure to an allergen. Even though anaphylaxis has
been on the rise for the past decade with reported rates of 350% in-
crease among food induced and 230% increase among nonfood in-
duced reactions, there is still paucity of data on the prevalence and
outcome of anaphylaxis in various populations.
OBJECTIVE
This study aims to; (i) assess the lifetime prevalence of anaphylaxis
among the paediatric population, (ii) identify the most at risk age,
and (iii) evaluate the main trigger for the condition in children.
METHODS
A descriptive cross-sectional study with a multistage stratified cluster
sampling of children aged three to eighteen was conducted in
Kuwait. 2828 registered students of both genders and all nationalities
in the selected governmental and private schools were sequentially
recruited in the school years 2014-2015 and 2015-2016 over a period
of 9 months to participate in the study.
RESULTS
The overall prevalence of anaphylaxis in the study population was
4.24 per 1000 with a 95% confidence interval of 1.85-6.64 per 1000
population. A total of 12 (0.42%) participants fulfilled all the criteria
for diagnosing probable anaphylaxis, out of which 66.7% were diag-
nosed during the incidence by a medical physician. Food was the
major trigger in 9 (75.0%) children overall, of which nuts was the
most common (33.3%), followed equally by milk and egg (16.7%)
and another 16.7% for other types of unspecified food. Medicine was
the trigger in 2 (16.7%) of them and one was not sure of the trigger.
CONCLUSIONS
Anaphylaxis in children is a stimulating and challenging subject re-
quiring targeted studies, starting with those assessing the prevalence
of this emerging serious disease, to those highlighting the lack of
availability, utilization and correct use of the treatment and the ne-
cessity of an emergency action plan.
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Although sublingual immunotherapy (SLIT) is increasingly used, data
on the efficacy of SLIT in pediatric asthma remain limited.
OBJECTIVE
To evaluate the effectiveness of co-seasonal specific SLIT in children
with allergic asthma and high IgE levels.
METHODS
Thirty children aged 3-17 years with allergic asthma and IgE > 600
IU/ml measured by IMMULITE 2000 XPi system (Siemens, Germany),
sensitized to house dust mites and molds were included in a 2-year
cohort study of the efficacy and safety of SLIT (Diater Laboratories,
Spain) using standardized sublingual extracts containing house dust
mites or molds (Alternaria alternata). Treatment efficacy was analyzed
using the score of symptoms such as difficulty in nasal breathing, rhi-
norrhea, sneezing, itching of the nasal mucosa (upper palate) and
discharge from the nose. Symptoms were measured before starting
treatment, and at 4, 12 and 24 months after starting immunotherapy.
RESULTS
SLIT significantly improved asthma symptom scores (61% vs. control
group), reduced nasal symptoms (45% vs. control group) and the use
of rescue medications (20% vs. control group), and improved FEV1
(in children aged ≥ 5 years), but had no effect on IgE serum levels
after 12 months of therapy. After the second year of SLIT, IgE serum
levels were reduced by 10% vs. controls. In the SLIT group, predom-
inantly local reactions were recorded in 32% of subjects in the first
year of treatment and in 12% in the second year: 42% of children in
the first year of SLIT and 18% in the second year had worsening of
atopic dermatitis. No patient had a systemic reaction during therapy.
CONCLUSIONS
The use of sublingual standardized allergen extracts of house dust
mites or molds (A. alternata) together with the clinical history (no his-
tory of anaphylaxis) make a correct diagnosis and the correct prescrip-
tion of immunotherapy possible in children with high IgE levels. Our
results show that co-seasonal SLIT in children with asthma and high IgE
levels was safe and reduced the multiple symptom medication score.
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BACKGROUND
There is limited knowledge regarding long term follow-up of milk al-
lergic patients who tolerate baked milk (BM) products.
OBJECTIVE
The aim of the study was to evaluate the long-term safety and effi-
cacy of this intervention.
METHODS
Children with IgE-mediated milk allergy underwent an oral challenge
with BM. Those who tolerated BM underwent baked cheese pizza
(BC) challenge after 6 months. Six months later, a challenge with un-
heated milk was offered to patients who tolerated BC.
RESULTS
85 children (median 5.2 years; range 15 months to 15 years) were pro-
spectively followed for a median of 29 months (range 15-50 months). Fif-
teen (18%) reacted to the initial BM challenge. Reactions were mild in
most cases an only 3 had anaphylaxis. Among 70 (82%) children who ini-
tially tolerated BM challenge, 26 (37%) tolerated unheated milk at last
follow-up, 16 (23%) tolerated BM/BC and 25 (36%) avoided all forms of
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were lost to follow-up. Predictive parameters of reactivity to initial BM
challenge include age (median - 7; range 2.5-15 years vs. 3.5; range 1-
14.5 years; P= 0.02), mild respiratory symptoms (67% vs. 26%, P<0.01) as
part of the reported allergic reaction to milk, asthma (53% vs. 14.3%, P<
0.01) and a larger SPT to casein (median 14; range 8-28 mm vs. 6; range
0-18 mm; P<0.01).
CONCLUSIONS
For most of our patients, ingestion of BM was found to be safe and well
tolerated. However, initial successful challenge with BM/BC does not al-
ways guarantee ongoing consumption of these products. Better predictors
of response are needed for patient selection and long term outcomes.
A6
Long-term follow-up of oral immunotherapy for food anaphylaxis
Sakura Sato1, Noriyuki Yanagida2, Motohiro Ebisawa1
1Department of Allergy, Clinical Research Center for Allergy and
Rheumatology, Sagamihara National Hospital, Kanagawa, Japan;
2Department of Pediatrics, Sagamihara National Hospital, Kanagawa,
Japan
Correspondence: Sakura Sato (s-satou@sagamihara-hosp.gr.jp)
World Allergy Organization Journal 2017, 10(Suppl 2):A6
BACKGROUND
Food anaphylaxis may be life-threatening.
OBJECTIVE
The aim of this study is to evaluate the efficacy and safety of oral immuno-
therapy (OIT) for treating anaphylaxis induced by allergy to hen’s egg (HE),
cow’s milk (CM), wheat (W), or peanut (P), with a long term follow-up.
METHODS
Children with HE, CM, W, or P anaphylaxis, confirmed by the positive
double-blind, placebo-controlled food challenge test, who received OIT
were enrolled. Patients were admitted to the hospital in initial phase. Subse-
quently, the dose was slowly increased to a maintenance dose (HE, one
heated-whole egg; CM [200 mL]; W, Udon noodle [200 g: 5.2g wheat pro-
tein]; P, peanut powder [3 g]) at home. Patients, who had ingested foods
without any symptoms, underwent the final oral food challenge (OFC) after
allergen avoidance for 2 weeks to confirm sustained unresponsiveness (SU).
If the final OFC was positive, OIT was continued while dwindling the food
intake interval (dwindling protocol). If patients did not have any symptoms,
they repeated the final OFC. We evaluated the proportion of SU based on
Kaplan-Meier analysis, and the safety of the dwindling protocol of OIT.
RESULTS
A total of 273 patients (HE; n = 84, CM; n = 114, W; n = 44, P; n = 31) were
enrolled. Median follow-up time was 5.3 years, and 69 patients (25%) were
lost to follow-up. The proportion of SU (%) was 87, 74, 64, and 57 in pa-
tients with P, W, HE, and CM anaphylaxes, respectively. The duration of
time to achieve SU (years) was 1.5, 1.8, 2.2, and 5.0 in patients with P, HE,
W, and CM anaphylaxes, respectively. One hundred nine patients contin-
ued the dwindling protocol of OIT. Of these patients, 33 patients (31%)
underwent the second final OFC. Adverse reactions were present in 10%
during the year after the first final OFC. Among them, mild symptoms
were 83%, moderate symptoms 16%, and severe symptoms 1%, and 6 pa-
tients needed to use adrenaline auto-injector at home.
CONCLUSIONS
Efficacy of OIT for food anaphylaxis was different among food anti-
gens, It was difficult to achieve SU during OIT for CM anaphylaxis
even in long-term treatment. Even if patients who experience food
anaphylaxis achieve desensitization by OIT, they have still a risk of
anaphylaxis by dwindling the food intake frequency, and these pa-
tients need careful management during OIT.
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To evaluate the effectiveness and safety of SLIT to HDM in children who
have asthma with allergic rhinitis (AR) and atopic dermatitis (AD).
METHODS
A total of 61 children aged 6-7 y.o. with co-morbid asthma were evaluated
and randomized to receive drugs with (n=32) or without (n=29) SLIT using
the sublingual spray with 50% of Dermatophagoides pteronyssinus and
50% of Dermatophagoides farinae in a standardized extract (Diater Labora-
tories, Spain). The clinical scores, physical examination, lung function were
assessed annually during 2 years of SLIT. Specific IgE against rDerp1,
rDerp2, rDerp10, methacholine challenge were performed at the begin-
ning and the end of the study.
RESULTS
The majority of patients had allergic asthma with AR (62, 3%) and AR, AD
(37,7%). Sensitization to either rDerp1, rDerp2 or rDerp10 had respectively
13, 1%; 19, 7%; 0% and both rDerp1 and rDerp2 were detected in 67, 2%
of children. During the first year of treatment there were no significant dif-
ferences in the clinical symptoms scores of AR and AD, but symptoms of
asthma were improved in 65, 6% SLIT group vs control group. A decrease
in the clinical symptom scores of asthma, AR and AD was observed in 84,
4%, 65, 6% and 66, 6% of children after 2 years of SLIT (p<0.05 vs control
group). There was no the significant deviations of FEV 1, sIgE levels to
HDM proteins during the study. The number of children with positive
methacholine challenge results decreased after 2 years specifically in the
SLIT group. SLIT was well tolerated with only local reaction reported.
CONCLUSIONS
HDM SLIT appears to be effective and safe in children with co-morbid
asthma and can simultaneously treat other target organs involved in the
allergic process. To achieve good control of asthma and allergic co-
morbidities, the use of more prolonged SLIT therapy is recommended.
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OBJECTIVE
To assess safety and efficacy of sublingual bacterial phenol inactivated
whole-cell suspension (OM1, Diater Laboratories, Spain) in adolescents
with CRS without nasal polyps (CRSsNP).
METHODS
39 patients aged 13- 16 were enrolled in this study. They were random-
ized to receive the sublingual bacterial phenol inactivated whole-cell sus-
pension of the following bacteria (OM1): Staphylococcus aureus, β-
hemophilic streptococcus, Streptococcus pneumoniae, Haemophilus influen-
zae (n=19) or the treatment according to World Allergy Organization rec-
ommendation (n=20). The clinical control of CRS, visual analogue scale
(VAS) score, number of antibiotics courses and bacterial cultures were per-
formed at pre-treatment and 12-month follow-up visits. The bacterial
counts graded by the laboratory from 103 to 105 CFUs/mL were analyzed.
RESULTS
The majority of patients had partly controlled 34 (87,2%) or uncontrolled
CRSsNP 5 (12,8%). According to VAS score included patients were divided
on moderate 30 (76, 9%) and severe 9 (23, 1%) CRSsNP. Staphylococcus
aureus colonization was noted in 31 (79, 5%) patients, both Staphylococcus
aureus and Streptococcus pneumoniae in 6 (15,4%), both Staphylococcus
aureus and Haemophilus influenzae in 2 (5,1%). There was a significant de-
crease in VAS score and increase in controlled CRSsNP particularly in OM
group (p<0.01). The number of antibiotics courses decreased in 33 (84,6%)
patients of OM group and only in 12 (30,7%) of control group. Reduction
of the bacterial count in Streptococcus pneumoniae-colonized and Staphylo-
coccus aureus-colonized adolescents was significant after the OM sublin-
gual therapy and was non-significant after use of standard drugs. No
adverse events related to OM therapy were observed.
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The sublingual bacterial inactivated whole-cell suspension appears to be
effective and safe in adolescents with CRSsNP and therefore can be con-
sidered an additional treatment option in patients with resistances to
standard treatment’s approach.
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BACKGROUND
The vast majority of health care professionals remain unaware of the nega-
tive effects of mouth breathing on normal facial growth and physiological
health in children. By adding a “mouth breathing” screen to existing 4 Year
Healthy Kids checks, we hypothesise that general practitioners (GPs) can
identify mouth breathing quickly preventing craniofacial growth abnormal-
ities, dental and orthodontic problems, poor posture, reduced exercise
capacity, sleep disordered breathing, fatigue, worsening of asthma, dry
mouth, reduced saliva and halitosis and below potential academic per-
formance. Typically adenoidal hypertrophy and allergic rhinitis are the
commonest cause of mouth breathing in children and allergy is a potential
modifiable risk factor.
OBJECTIVE
To evaluate the possible role of GPs in performing comprehensive mouth
breathing screening tests at preschool age to identify mouth breathing
and prevent chronic complications of allergic rhinitis.
METHODS
Create an evidence-based algorithm for mouth breathing to be used by
GPs as a clinical pathway which could successfully identify chronic compli-
cations of allergic rhinitis and sleep disordered breathing. Determine
whether after completing the 6 months accredited GP training program in
Allergy/ENT GPs could successfully learn and apply skills such as nasoen-
doscopy, rhinomanometry and allergy skin prick testing to successfully
perform the clinical pathway.
RESULTS
All GPs enrolled in the training program were successfully trained to per-
form the mouth breathing clinical pathway which included paediatric
focussed allergy and ENT history, examination of oral cavity and nasopha-
ryngeal airway assessment with nasoendoscopy, identifying allergic rhinitis
and co-ordinating a multidisciplinary approach to mouth breathing involv-
ing ENT for adenoidectomy and/or adenotonsillectomy as well as allied
health involvement such as orthodontic and myofunctional therapy and
speech pathology.
CONCLUSION
Mouth breathing is a pathology and not a variant of normal and warrants
a comprehensive examination identifying allergic rhinitis, adenoidal hyper-
trophy and/or functional mouth breathing. GPs are in the best position to
screen for mouth breathing when performing routine oralchecks at the 4
Year Healthy Kids Check. GPs were able to identify causes of mouth
breathing as well as comprehensively treat and co-ordinate care with ENT,
allergists, orthodontists and oromyofacial therapists.
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High Dose Subcutaneous Immunotherapy (SCIT) has proven effect-
iveness; however, due to its cost allergy vaccines are not available
for low-income patients.
OBJECTIVE
This fact encouraged us to perform a “proof-of-concept” study of a
HDM lower weekly dose to be administered intradermally (IDIT, con-
taining Dermatophagoides pteronyssinnus/Dermatophagoides fari-
nae (Dp/Df) and Blomia tropicalis (Bt)) in pediatric allergic rhinitis
patients symptomatic on exposure to house dust.
METHODS
Symptomatic subjects with no previous immunotherapy (SLIT/ SCIT)
use were selected. All subjects had positive prick skin tests (> 3 mm
wheal) to a Dp/Df mixture (10.000 AU/ml) and Bt (30.000 DBU/ml)
and negative prick skin tests to dog and cat epithelia, cockroach and
grasses. No tobacco exposure or pets at home were allowed. All chil-
dren received a 0.05 cc weekly IDIT dose containing 83 AU of Dp/Df
mixture (0.5 micrograms HDM major allergens) and 250 DBU of Bt.
All patients filled out a daily Symptom Score and a Visual Analog
Scale (VAS) chart for 2 weeks before IDIT treatment was commenced,
and the day before the weekly dose administration, for 12 weeks.
Serial dilutions prick skin tests (SDSPT) were performed before and
after the IDIT treatment. Statistical comparisons of quantitative vari-
ables (mean values) were made between total nasal symptom scores
(TNSS), VAS, and wheal size (SDSPT) before and after treatment,
employing the Mann-Whitney test with a P<0.05 considered statisti-
cally significant.
RESULTS
Eight patients completed the study. TNSS and VAS scores were found
to be significantly lower when compared to pre-treatment week;
also, SDSPT wheal sizes were significantly lower on post-treatment
evaluation.
CONCLUSIONS
This “proof of concept” study shows significant improvement in
symptoms of allergic rhinitis in patients that received a 14 fold less
weekly IDIT dose (0.5 μg), for 12 weeks, when compared to the re-
ported SCIT effective maintenance dose of 0.5cc (7 μg of HDM Major
Allergens). An immunologic response, as evidenced by SDSPT, as a
correlate of improvement, was also observed. A lower weekly dose
IDIT has a favorable clinical impact at a fraction of the conventional
SCIT dose; it might be considered as a cost-effective alternative treat-
ment for developing countries.
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BACKGROUND
Food allergy prevalence is increasing in developed countries, but
these results have not yet been verified in developing countries, es-
pecially in india.
OBJECTIVE
Our aim was to determine whether the prevalence and characteris-
tics of food allergy have changed over the last 7 years in Bathinda,
India.
METHODS
Two cross-sectional studies were performed, 7 years apart (2009 and
2016) using the same diagnostic methods in the same age group (0–
24 months) of the same hospital. A total of 401 infants were ran-
domly selected for the present study. Food allergy was confirmed by
food challenge. SPSS 15.0 was used to analyze the difference in
prevalence.
RESULTS
Food allergy prevalence increased significantly from 3.5% in 2009 to
7.7% in 2016 (P= 0.017). The prevalence of a positive skin-prick-test
response was also increased (from 9.9% to 18%; P= 0.002). Egg and
World Allergy Organization Journal 2017, 10(Suppl 2):39 Page 5 of 16cow’s milk were still the most common food allergens, which cause
skin and gastrointestinal symptoms in most infants.
CONCLUSIONS
This is the first study in India to indicate time trends in food allergy
prevalence and characteristics. Our data show that in the 7-year
period from 2009 to 2016, the prevalence of food allergy seems to
have increased in India.A12
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BACKGROUND
Prospective real-world data are important to supplement clinical trial
data in heterogeneous diseases like asthma. Data for adolescents are
essential, as they are often under-represented in clinical trials.
METHODS
69 patients aged between 12-17 years old with asthma, identified as
omalizumab candidates by their treating physicians and with access
to omalizumab through insurance or other funding, were enrolled as
part of the PROSPERO study. Patients were followed for a maximum
of 48 weeks. At baseline and throughout the study, asthma-related
healthcare utilization and exacerbations, were recorded. Asthma con-
trol was recorded monthly using the Asthma Control Test (ACT). Spir-
ometry was performed and biomarkers (FeNO, blood eosinophils)
were collected at baseline, 6 months and end of the study.
RESULTS
59 (86%) adolescents completed 48 weeks of the study; mean (SD)
age 14.0 (1.69) years, primarily male (64%) and white (58%), with
33% Black or African American. On average, adolescents reported 2.8
exacerbations (67% with ≥ 2 exacerbations) that required oral cor-
ticosteroid use, ED visit or hospitalization in the 12 months prior to
enrollment. 28% reported ≥ 1 asthma related hospitalization in the
prior year. At month 12, a mean rate of 0.46 exacerbations per year
was observed, representing an 84% reduction from baseline. 11.5%
of patients reported ≥ 2 exacerbations and 4% reported ≥ 1
hospitalization, an 83% and 86% reduction from baseline. Mean (SD)
baseline FEV1 percentage predicted was 88% (17) and improved on
average by 8% to 95% (20), an absolute improvement of 160mLs
compared with baseline. 71.6% (48/67) of adolescent patients with
baseline ACT data reported poorly controlled asthma at baseline
based on ACT score of <20. At the study’s conclusion, 68.8% of these
poorly controlled patients were controlled (ACT ≥ 20). Baseline mean
(SD) FeNO levels were 38.4 (39.4) ppb and mean (SD) eosinophils
were 316 (210) cells/μL, with 54.5% of patients having eosinophils ≤
300 cells/μL. Median (interquartile range) total IgE levels were 507
(960.7) IU/mL. At the end of study, mean (SD) FeNO levels decreased
by 27% to 29.2 (28.1) ppb and mean eosinophils (SD) decreased by
34% to 209 (151) cells/μL. Adverse events were consistent with the
safety profile described in the current product label.
CONCLUSIONS
In a real-world setting, adolescents treated with omalizumab had sig-
nificant improvements in asthma control as demonstrated by de-
creased exacerbations and hospitalizations, and improved ACT scores
compared with baseline.A13
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OBJECTIVE
We had followed up a birth cohort in Sagamihara-city to clarify pro-
files of allergic diseases during the first 7 years of life from 2002. We
began to follow the same cohort again from 2014 with a 12 year
interval. The purpose of the current survey is to clarify changes in
prevalence of infantile allergic diseases and environmental factors,
compared with data from 2002.
METHODS
Using the mass medical examination system at the age of 4
months (m), we obtained basic profile information on subjects
from January 1, 2014 to December 31, 2014. We have followed
up the subjects whose parents had agreed to participate in this
study at the ages of 8 and 12 m. We utilized the same ques-
tionnaire on atopic dermatitis (AD) and food allergy (FA) that
was mailed in 2002.
RESULTS
The number of subjects in the 2014 study was 4,646 with a recovery
rate of 83.9% (2002 study: 5,247 with a recovery rate of 88.5%). We
analyzed cases that answered 3 times at 4, 8, 12 m old, except for in-
complete answers. There were 2,529 cases in the 2014 study and
compared the results with 3,196 cases in the 2002 study. The inci-
dence of eczema with suspected AD was 19.6%/ 17.0%/ 15.5% at 4/
8/12m, respectively (26.3%/ 18.7%/ 13.0% in 2002). The rate of diag-
nosis of AD was 1.0%/ 2.6%/ 3.1% (1.2%/ 2.8%/ 3.2% in 2002). “Re-
ported FA” includes a case with eliminating foods or using special
milk due to FA. The rate of “Reported FA” was 8.8%/ 18.8%/ 19.7%
(6.6%/ 19.1%/ 14.6% in 2002). The rate of diagnosis of FA was 0.1%/
1.2%/ 1.5% (0.1%/ 2.3%/ 2.7% in 2002). We detected significant
changes of environmentaL factors in 4 m old infants with a 12 year
interval. The rate of positive family history with allergic disease, the
rate of raising pets and the rate of breast feeding only cases in-
creased. The average of weight, the rate of indirect cigarette expos-
ure, the rate of artificial feeding only cases and the rate of first child
decreased.
CONCLUSIONS
There was no statistically significant difference between the 2002
and 2014 studies regarding the rate of diagnosis of AD. “Reported
FA” cases increased at 4 and 12 m significantly; on the other hand,
diagnosis of FA was reduced significantly at 8 and 12 m.
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BACKGROUND
Wheat is the third most common cause of food allergy in Japanese
children. But there are few reports of oral immunotherapy (OIT) for
wheat allergy.
OBJECTIVE
Here we report about our rush OIT of wheat for school-age children
of severe wheat allergy with anaphylaxis.
METHODS
Subjects were 6 boys and 1 girl (6 to 10 years of age) of wheat al-
lergy. Their threshold doses of wheat inducing allergic reactions were
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1g of UDON contains 25mg of wheat protein). The wheat specific IgE
value was 5.46-100< UA/ml.
All subjects were hospitalized during rush OIT. Intramuscular adren-
aline, oral antihistaminics and corticosteroid, oxygen, and broncho-
dilator for inhalation were ready to be used at the bedside at all
times. The initial dose for each subjects was set at approximately
one-eighth to one-half of the threshold dose for that subjects. There-
after, doses were increased by 1.5 times and administered twice a
day at 1 hour interval. The goal of rush OIT was 80 to 180 g of wheat
noodle according to their age and families’ choice. For preventive
therapy, DSCG was used in three subjects and leukotriene receptor
antagonist was used in six subjects, and antihistaminic agent was
used in all subjects.
RESULTS
All subjects acquired desensitization to target dose of rush OIT (80 to
180 g of wheat noodle). It took 2 to 4 weeks. No serious reactions
which needed epinephrine injection were observed. Medication (2.6
antihistaminic agents/person, 1.0 corticosteroid medicine/person)
and inhalation treatment (0.7 times/person) were required for the
treatment of adverse reaction accompanying rush OIT (rash, cough,
wheezing, stomachache, diarrhea, etc). All subjects continued OIT
after discharge from hospitals.
CONCLUSIONS
Our rush OIT was a safe and effective treatment for severe wheat
allergy.A15
Cow’s milk allergy in cystic fibrosis children
Liviu L Pop1,3, Ioana-Mihaela Ciucǎ1,3, Liviu Tǎmaş2, Marilena Lazarescu3,
Corina Pienar1
1Department of Pediatrics II, Victor Babeş University of Medicine and
Pharmacy Timisora, Timisoara, Romania; 2Department of Biochemistry,
Victor Babeş University of Medicine and Pharmacy Timisora, Timisoara,
Romania; 3National Cystic Fibrosis Center, Timisoara, Romania
Correspondence: Liviu L Pop (liviupop63@yahoo.com)
World Allergy Organization Journal 2017, 10(Suppl 2):A15
BACKGROUND
In cystic fibrosis (CF) an important feature is the pancreatic insuffi-
ciency expressed by steatorheea; in some cases, despite enzyme sup-
plementation the chronic diarrhea is poorly controlled.
OBJECTIVE
Considering the increasing frequency of cow’s milk allergy (CMA), we
consider it interesting to find the prevalence of cow’s milk allergy
among patients with CF.
METHODS
In one year, sixty seven children with CF, aged 1 month - 3 years (19
infants), followed in our center were observed for CMA. Cow’s milk
allergy was suspected in the presence of specific clinical manifesta-
tions (gastrointestinal symptoms, cutaneous signs, respiratory fea-
tures), or suggestive medical history (failure to thrive, colics etc). In
addition CMA-specific IgE (α- and β-lactoglobulin, casein) and diag-
nostic elimination tests were performed.
RESULTS
Among infants, CMA was diagnosed in 47.36% (9 patients) of chil-
dren, predominantly in pancreatic insufficient children (77% -CF in-
fant with pancreatic insufficiency). Toddlers (1-3 years) were
diagnosed in a smaller percent, only 16.6% (8 children) proved to
have CMA, although in more than 35% of toddlers, a positive history
for CMA diagnosis was found. CF patients with pancreatic insuffi-
ciency associated more frequently CMA (88.23%) than cystic fibrosis
patients pancreatic-sufficient. The prevalence of cow’s milk allergy
was important, cumulating a 25.37% of CF patients.
CONCLUSIONS
Cow’s milk allergy was frequently found in CF children, especially as-
sociated with pancreatic insufficiency. The “combined” enteropathy
could influence the disease’s outcome and should be considered es-
pecially in persistent diarrhea of CF children with correct enzyme
supplementation.A16
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BACKGROUND
Zonulin, an epithelial tight-junction regulator, plays an important role
in the regulation of epithelial barrier function and was reported to
play a pathogenic role in celiac disease and other chronic inflamma-
tory diseases. Allergic sensitizations are the most important risk fac-
tors for development of allergic diseases. Allergen penetration
through epithelium to the body is important for allergic sensitiza-
tions (cf.percutaneous sensitization to food allergens). Because aller-
gen sensitization and chronic inflammation are important in the
pathogenesis of allergic diseases, zonulin is suggested to paly im-
portant roles in allergic diseases. But there are few reports about
zonulin levels in pediatric allergic patients.
OBJECTIVE
The aim of this study was to investigate the relationship between
serum zonulin levels and allergic diseases in children.
METHODS
The study included allergic children and healthy children who were
of similar age and gender distribution (8 healthy infants and 8 aller-
gic infants, and 8 healthy school-age children and 8 school-age aller-
gic children). The serum zonulin level was measured by ELISA.
RESULTS
In this study, total IgE levels in all allergic patients and healthy chil-
dren were above normal levels and below measurable limits, respect-
ively. All allergic infants had atopic dermatitis and food allergy, and
allergic school-age children had food allergy or bronchial asthma or
both. In infants, mean zonulin levels were 30.5 ng/ml in allergic pa-
tients and 17.8 ng/ml (p=0.0028). In school-children, mean zonulin
levels were 29.8 ng/ml in allergic patients and 8.7 ng/ml (p<0.0001).
We also investigated whether zonulin levels are different among al-
lergic diseases.
CONCLUSION
In infants and school-age children, serum zonulin levels are higher in
allergic children than that in healthy children.
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BACKGROUND
The Great East Japan Earthquake on March 11, 2011 brought exten-
sive damage to northeast Japan. Essential utilities were damaged
and a lot of people were forced to evacuate. They had to stay at the
temporary evacuation shelter and take ration foods. However, refu-
gees with food allergy could not eat the foods because the ration
foods were supplied without considering food allergy. According to
the reports, the caregivers of children with food allergy were con-
fronted with difficulties to get allergen-free foods, and actually some
children developed allergic symptoms.
OBJECTIVE
Pack cooking attracted lots of attention in Japan after The Great East
Japan Earthquake, because the cooking method enables cooking by
portable gas stove and with less water. Since the ingredients are
changeable in each bag, pack cooking is convenient to make individ-
ual foods. In this report, we emphasize the usefulness of pack
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we show that the allergen cross-contamination hardly occurred
among the bags by the ELISA analyses.
METHODS
Recipes of pack cooking without 7 specified raw materials for food
allergy in Japan (eggs, milk, wheat, peanuts, buckwheat, shrimps and
crabs) were designed. All recipes were cooked at the test kitchen of
Matsumoto University. Ingredients were thinly sliced and put into a
plastic bag made of polyethylene with seasonings. The top of the
each bag was twisted and closed tightly. Then the bag was cooked
in boiled water for about 30 minutes until the ingredients were fully
cooked. To estimate the contamination of the allergens during cook-
ing, the bags contained 5 food allergens; eggs, wheat, buckwheat,
shrimps and crabs were boiled together with the allergen-free bags
containing some ingredients. The amount of allergens was assessed
by the commercially available ELISA kits for each allergen.
RESULTS
We will show 20 recipes for the allergen-free pack cooking menu at
the session. The ELISA analyses revealed that no wheat allergen was
detected in the ingredients bags at all. Concerning the other 4 aller-
gens, little contamination was observed. Different analysis of
methods such as the western blot or PCR were required to exclude
the non-specific reaction. Subsequently, we are developing the
weaning food’s recipes because it is also very difficult to get foods
for babies at the time of disaster. We will show the latest data on
site.
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BACKGROUND
Airborne fungal spores are one of the most important allergen
sources worldwide.
OBJECTIVE
The present study aimed to investigate the seasonal variations of air-
borne fungal spores found in indoor and outdoor environments of
urban and rural areas of West Bengal and to determine allergenic po-
tency of Aspergillus terreus through immuno-biochemical and in silico
methods.
METHODS
Aerobiological monitoring was performed using Andersen and Bur-
kard Personal sampler for trapping viable and non-viable spores from
the air of Kolkata (Urban) and Habra (Rural), West Bengal, India. A
questionnaire survey and hospitalization data were collected from
the Habra State General Hospital. Protein from A. terreus, dominant
aero-spore in the studied area, was extracted for determining its
allergenecity by SPT, ELISA and histamine release assay. Protein pro-
file of A. terreus was analyzed by 1D and 2D gel electrophoresis,
followed by the immunoblotting with 15 individual sensitized pa-
tients’ sera and identification of allergenic spots through MASCOT
analysis. One of the allergens has been purified for further biochem-
ical study, followed by in silico allerginicity assessment using bioinfor-
matics tools.
RESULTS
The comparative study revealed that the rural area showed max-
imum spore load as compared to the urban area. The survey and
hospitalization records (ARI, COPD patients) were found to be posi-
tively correlated with the total spore load. Histamine release, specific
IgE and skin sensitivity were also found in higher amount in suscep-
tible patients. 2D gel blot revealed sixteen spots as immuno-reactive
upon immunoblotting with sensitized patients’ sera. MALDI TOF/TOF
analysis led to the identification of 3 allergens as BMH2 (similarity
with 14-3-3 protein), triose phosphate isomerise and glutathione S-
transferase. Purification of a phosphotriose isomerase protein wascarried on due to its highest IgE reactivity, followed by the prediction
of their epitopes using allergen prediction servers.
CONCLUSIONS
This study will help to determine the presence of the diversified fun-
gal species and their total concentrations in the air of the sampling
site. In West Bengal, A. terreus is the commonest among fungi and
three allergens have been reported from this fungus.
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BACKGROUND
Occurence of food allergy has significantly risen in recent decades. Its
prevalence is 6-8% in children. There are some differencies in incidence of
types of food allergy in different geographical areas. Only limited data are
known about the most common causes of food allergy in Czech Republic.
OBJECTIVE
The aim of the study is to gather epidemiological data describing pa-
tients with food allergy in the Czech Republic.
METHODS
DAFALL- Database of Food Allergies - is an electronic registry
founded in October 2014. The most common triggers of food reac-
tions, threshold doses, processing of food allergens, laboratory test
results including component resolved diagnosis, skin prick tests and
food challenges results as well as allergology history of the patients
were evaluated.
RESULTS
During the first 28 months until February, 2017, 1,276 patients were en-
rolled from more than 30 collaborating allergology outpatient clinics; 49%
children under age of 6 years (n=624), 26,5% children aged 6-18 years
(n=337) and 24,5% adults (n=315). In children under 1 year of age, cow’s
milk is the most frequent food allergen. In 86% of cases, first symptoms of
milk allergy were recorded below age of 7 months and in 60% of cases
were noted in fully breast-fed kids. About 60% of milk reactions were non-
IgE mediated, with no prove of any positivity in skin prick tests and/or spe-
cific IgE against milk. Most common triggers of allergy in children between
1 and 6 years of age were milk (40%), egg (34%), tree nuts (22%), peanut
(17%) and fruits (11%). In patients older than 6 years, significant allergens
are tree nuts (hazelnut, walnut, almond), fruits (apple, peach, kiwi), vegeta-
bles, peanut and seeds, mainly the sesame seed and poppy seed. The
poppy seed is one of the typical Czech food allergens in all ages. On the
other hand, we found only very limited number of patients with adverse
reactions to soy.
CONCLUSIONS
DAFALL is the first project describing relevant data on food allergy in
the Czech population. The projected period for data collection is 3
years and we expect to enroll 1500-2000 patients. More than 70% of
patients enrolled are children, so we will be able to give a detailed
description of the Czech food allergic children.
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Societies worldwide are faced with a progressive increase in
immune-mediated health problems such as allergic, autoimmune
and inflammatory diseases, as well as obesity. Perinatal administra-
tion of specific probiotic bacteria is an attractive approach in redu-
cing the risk of these conditions, but long-term efficacy and safety
data are lacking.
OBJECTIVE
The aim here was to evaluate the clinical benefit and long-term
safety of specific probiotics administered during the perinatal period.
METHODS
The probiotic strains used were Lactobacillus rhamnosus GG (LGG),
Bifidobacterium lactis Bb-12, Lactobacillus paracasei ST11 and Bifido-
bacterium longum BL999. The children involved have subsequently
undergone prospective long-term follow-up. In addition to physical
examination, data were collected by structured questionnaires on
non-communicable diseases and continued probiotic use.
RESULTS
Altogether, 303 mother-infant pairs were included in the analysis. Al-
lergic disease was the most common chronic condition with an over-
all prevalence of 51.2%. It consisted in allergic rhinitis (prevalence
42.3%), atopic eczema (18.9%), asthma (12.7%) and food allergy
(1.4%). In children given specific probiotics or probiotic combinations
perinatally there was a tendency to a decreased prevalence of aller-
gic disease, OR 0.67, 95% CI 0.43-1.06, p=0.09. In those receiving LGG
perinatally the decrease in the prevalence of allergic disease (59/133,
44.4%), as compared to placebo (79/140, 56.4%), was statistically sig-
nificant, OR 0.62, 95% CI 0.38-0.99, p=0.047. The prevalence of
asthma in the children receiving probiotics perinatally, 9.3%, was not
statistically different from that in children given placebo, 15.8%; (OR
0.55, 95% CI 0.24-1.25, p=0.15), nor was the prevalence of asthma in
children receiving perinatally LGG alone or in combination (10/96,
10.4%), statistically different from that in children given placebo (18/
114, 15.8%); (OR 0.62, 95% CI 0.27-1.42, p=0.26).
CONCLUSIONS
Perinatal probiotic administration is safe in long-term follow-up. Chil-
dren receiving Lactobacillus rhamnosus GG perinatally tended to have
decreased allergy prevalence.
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OBJECTIVE
Colocasia antiquorum, or eddoe, is a tropical vegetable found pre-
dominantly in China, Japan and the West Indies. It is considered a
more flavourful alternative to potato or yams. We report one of the
first cases of a patient with an allergic reaction to eddoe.
METHODS
I.R is a 10-month-old female with atopic dermatitis, who was referred
to a local allergist for an episode of emesis almost immediately after
ingestion of eddoe on two separate occasions. Milk was ingested
with eddoe on one of these occasions. She also reports swollen lips,
urticaria and vomiting within 3 hours of ingestion of eggs. Skin test-
ing was performed to fresh peanut, milk extract, fresh milk, egg ex-
tract, fresh egg and fresh eddoe.
RESULTS
Skin testing to fresh peanut, milk extract, fresh milk, egg extract,
fresh egg and fresh eddoe was positive to fresh egg (16mm) and
fresh eddoe (5mm). The patient was instructed to avoid eggs and ed-
does and an Epi pen Jr was prescribed.
CONCLUSIONS
To our knowledge, this is one of the first case reports of an aller-
gic reaction to Colocasia Antiquorum, or eddoe. Further research
is needed to characterize the allergenic components of this
vegetable.CONSENT TO PUBLISH
Consent to publish was obtained from the parents of the patient in
this study.A22
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OBJECTIVE
The aim has been to evaluate the safety of Beltavac Polimerizado® of
mites in young children after administration of a rush schedule and
efficacy after nine months of treatment.
METHODS
This is a retrospective observational study with an evaluation of 40
medical histories of children between 3 and 11 years whose were di-
agnosed with rhinoconjunctivitis and/or bronchial asthma by
sensitization to mites. These children had been treated with Beltavac
Polimerizado® (mix Dermatophagoides pteronyssinus and Dermatopha-
goides farinae) in a rush schedule (0.2 + 0.3 ml with an interval be-
tween doses of 30 minutes and 0.5 ml as maintenance dose after
one month). The mean age of children was 7.1 years and diagnosis
was rhinitis + asthma (50%), rhinitis (25%), asthma (15%), rhinocon-
junctivitis + asthma (5%), rhinoconjunctivitis (5%). The variable of
study to evaluate safety was the number of adverse reactions per
dose classified according to EAACI criteria. The variables used to
evaluate efficacy were the clinical status of the patients, medication
use and specific IgE and IgG4 values after nine months of treatment.
This study was classified as EPA-OD by AEMPS and evaluated and ap-
proved by the ethics committee of Hospital Virgen de la Arrixaca in
Murcia.
RESULTS
In relation to safety 6 adverse reactions in the 120 doses adminis-
tered were observed (5%). The classification of adverse reactions
was: two immediate local reactions (<5 cm), three delayed local reac-
tions (one <5 cm; two between 5-10 cm) and one systemic reaction
(grade 1). All patients tolerated the maximum dose and there was no
treatment suspension.
Regarding efficacy, there was a clinical improvement in all patients
and reduction of use of medicines in 85% of patients after nine
months of treatment. There were no statistically significant differ-
ences in total and D. pteronyssinus, D. farinae, Der p 1 specific IgE,
but was a statistically significant reduction of Der p 2 specific IgE. In
relation to IgG4 there was a statistically significant increase of spe-
cific D. pteronyssinus and D. farinae IgG4.
CONCLUSIONS
The treatment with Beltavac Polimerizado® of mites administered by
a rush schedule is safe in children between 3 and 11 years. The clin-
ical and immunological data showed an efficacy of this treatment.A23
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BACKGROUND
Twenty-three to 70% of individuals with pollen allergy experience
enoral symptoms after eating raw fruits and vegetables. The oral al-
lergy syndrome (OAS) reflects a phenomenon based on the cross-
reactivity of specific IgE antibodies towards epitopes of certain pollen
and food proteins. Improvement of the OAS in pollen-allergic sub-
jects using specific immunotherapy (SIT) has been reported to be
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OAS mainly focused on apple following birch pollen immunotherapy.
OBJECTIVE
We aimed to investigate the effect of SIT on OAS.
METHODS
Fifteen birch or mugwort pollen-allergic subjects with OAS who re-
ceived SIT at least 1 year were surveyed by questionnaire. Skin prick
test and serum specific IgE to birch or mugwort pollen were
determined.
RESULTS
Eight of 15 (53%) showed improvement of OAS. Skin-test reactivity
and specific serum IgE to pollen decreased in 70% and 67% of the
subjects, respectively. The subjects with improvement of OAS were a
higher proportion of female and lower serum total IgE levels than
those without improvement. There was no significant difference in
skin-test reactivity, specific serum IgE, and SIT duration. The symptom
score of OAS was significantly correlated with which of allergic
disease.
CONCLUSIONS
SIT with birch or mugwort pollen improved OAS. Female and low
serum total IgE may be related with SIT impact on OAS.
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BACKGROUND
Dermatophagoides pteronyssinus (Der p) and Dermatophagoides fari-
nae (Der f) are two common species causing sensitization in children
with asthma and allergic rhinitis. In vitro studies have demonstrated
IgE-binding crossreactive epitopes between two species. Currently,
Der p and Der f are both commercially available extracts for skin
prick testing. However, there are few studies evaluating the concord-
ance and correlation of skin test reactivity to these allergens in
children.
OBJECTIVE
The purpose of this study was to assess agreement of sensitization
between Der p and Der f allergen extracts in children. Correlation of
skin test responses in wheal diameters between them was evaluated.
METHODS
This study was a retrospective medical chart review of the skin prick test
results among children aged 2 to 18 years old who presented with symp-
toms suggestive of allergic rhinitis and/or asthma at the Pediatric Allergy
Clinic of Thammasat Hospital, Pathum Thani, Thailand. All patients under-
went skin prick test with Der p and Der f commercial allergen extracts.
Sensitization was defined as > 3 millimeters in wheal diameter from skin
prick testing. The kappa was used to evaluate the agreement of
sensitization and Spearman analysis (rho) was used for assessing the cor-
relation of mean wheal diameter between both extracts. The patients were
divided into 3 groups; preschool (2-6 years old), school-aged (7-12 years
old) and adolescent (13-18 years old) for analysis skin test reactivity ac-
cording to the age group.
RESULTS
Of the 280 patients, 181 (64.6%) were male. The mean age was 7.6 ±
3.5 years. 267 (95.4%) patients had allergic rhinitis and 72 (25.7%)
had asthma. 157 (56.1%) of patients were positive to Der p and 146
(52.1%) were positive for Der f, respectively. The correlation of meanwheal diameter between Der p and Der f allergen extracts showed
strong correlation, all age (rho = 0.9; p < 0.001), preschool (2-6
years old; rho =0.92; p < 0.001), school-aged (7-12 years old; rho
= 0.88, p < 0.001) and adolescent (13-18 years old; rho=0.89, p <
0.001). The agreement of sensitization between Der p and Der f
was substantial to almost perfect, all age (kappa=0.83), preschool
(2-6 years old; kappa=0.87), school-aged (7-12 years old; kappa=
0.83) and adolescent (13-18 years old; kappa = 0.72), respectively.
CONCLUSIONS
This study showed a strong correlation and substantial to almost per-
fect agreement of sensitization on skin test response between Der p
and Der f in children. A trend of agreement was decreased with in-
creasing age when stratified by age group.
A25
The lymphocyte activation test – Clinical utility in delayed skin
reactions in paediatric age group: A prospective study
Krasimira Baynova, Marina Labella, Teresa De Aramburu, Manuel Prados
Allergy Unit, University Hospital Virgen del Rocío, Seville, Spain
Correspondence: Krasimira Baynova (krasi1024@yahoo.com)
World Allergy Organization Journal 2017, 10(Suppl 2):A25
BACKGROUND
Drug hypersensitivity reactions (DHR) are classified as immediate and
non-immediate/delayed reactions, depending on their onset during
treatment. Non-immediate drug-induced skin reactions in children
are not common but they suppose a challenge in our daily practice.
Drug provocation test (DPT) cannot be considered in many occasions
because of the risk of severe reactions. Safer in vitro tests are being
sought in order to establish the diagnosis in non-immediate DHR.
OBJECTIVE
Our aim was to evaluate the utility of the lymphocyte activation test
(LAT) in the diagnosis of delayed skin DHR in children.
METHODS
We prospectively studied 32 children (from 1 to 18- year-old) who
consulted us for suspect delayed mild-moderate skin DHR. The in-
volved drugs were beta lactam antibiotics, non beta lactam antibi-
otics and nonsteroidal anti-inflammatory drugs (NSAIDs). DHR had
occurred 4 weeks-1 year before testing. To all patients we performed
patch test, LAT and previous informed consent was signed by the
parents - a DPT.
To carry out the LAT, peripheral mononuclear patient’s cells were iso-
lated and incubated with the studied drug during 48 hours. We eval-
uated the surface molecule CD69 by flow cytometry as an in vitro
indicator for T-cell lymphocyte activation.
RESULTS
34 LAT were performed (few drugs involved in some patients). 25 of
them had a negative result and 24 of the respective DPT were nega-
tive too (predictive negative value – 96%). 9 of the performed LAT
had a positive result and showed a low positive predictive value
(11%) when DPT was carried out, just 1 of the DPT was positive too
(mild cutaneous reaction). None of the patch test was positive.
CONCLUSIONS
LAT has an excellent predictive negative value in our group of pa-
tients. LAT would be useful in cases of delayed skin DHR when the
child was polimeidacted and all involved drugs had to be studied
cautiously to find the culprit drug and to reject the involvement of
the rest of the drugs. Further studies are needed to confirm our
findings.
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The prevalence of allergic diseases and the severity of symptoms
continue to increase worldwide, and velocity of propagation is high-
est in children. Above the burden on the society, allergic diseases
hold a key position with regard to the burden at individual and fam-
ily level. However, formal studies on the psychosocial impacts of al-
lergic disorders on subjective wellbeing of children remain obscure.
Severity of allergic disease is approximated by the extent of symp-
toms in daily life and patients’ perception of well-being.
METHODS
The cross-sectional study included 1,947 children from Finland, which
is a subsample of the worldwide Children’s Worlds, the International
Survey of Children’s Well-Being (ISCWeB). A randomly selected, na-
tionally representative data collection was completed in 2016. Two
psychometric wellbeing scales (SLSS, BMSLSS) were applied to deter-
mine the connection between allergic diseases and life satisfaction
of 10- to 12-year-old children.
RESULTS
Finnish children evaluated their well-being as excellent; more than
80% of 10- and 12-years-olds are very satisfied with their lives. Espe-
cially children with atopic dermatitis (24%) were more likely to report
reduction both in SLSS life satisfaction than those with no atopic
dermatitis (6% vs. 11%, OR = 1.77, 95% CI = 1.23 - 2.56, p = 0.0021)
and BMSLSS life satisfaction (14% vs. 20%, OR = 1.52, 95% CI = 1.15
– 2.0, p = 0.0029). In multiple linear regression analysis, life satisfac-
tion, as measured by SLSS (F (8, 1545) = 6.92, p < .0001, R2 = .0296)
and BMSLSS (F (8, 1445) = 13.82, p < .0001, R2 = .0659), was associ-
ated with younger age, working parents, not having atopic derma-
titis, and practicing sports regularly.
CONCLUSIONS
Active allergic disease reduces a child’s own perception of wellbeing.
Results highlight the importance of early diagnosis and treatment.
More attention should be paid to the psychological status and treat-
ment compliance in children with allergic disease.
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BACKGROUND
Children are bearing the brunt of a dramatic increase in incidence of
allergic diseases in the developing world, including India. Indoor al-
lergens derived from dust mites, cockroaches, rodents, pets and
fungi are associated with asthma and allergic diseases. Allergen
avoidance is a crucial component in the management of these condi-
tions. There is little data from India on indoor allergens and exposure
levels that trigger symptoms.
OBJECTIVE
The study aims to identify and quantify indoor allergens in homes of
children with proven allergic disease in urban India.
METHODS
The study has been designed to cover 20 Indian cities with different
climatic conditions. Phase 1 participants were recruited from a
pediatric allergy clinic in one of the cities (Bangalore). Children with
features of allergic disease testing positive to one or more allergens
by skin prick testing (SPT) were included. Dust samples from homes
of patients and non-allergic controls were collected using DUSTREAM
® collectors. Analysis for the presence of allergens was done by
MARIA (Multiplex Array for Indoor Allergens) assays.
RESULTS
Samples from 10 controls and 25 cases were analysed. The allergens
assayed were Der p1, Der f1 MG2, Can f1, Fel d1, Mus m1, Rat n1, Blag2, Alt A1 and Asp f1. Majority of homes had significant levels
(>2mcg/gm dust) of house dust mite (HDM) allergens with over 2/
3rds having very high levels (>10mcg/gm dust). Levels of other aller-
gens were relatively low. Allergen levels were similar in homes of
both cases and controls.
CONCLUSIONS
This is the first study of its kind in India. Most children with allergic
disease in this urban setting were sensitised to HDM Allergens. The
majority of the homes had significant levels of HDM allergens. How-
ever, high level of environmental exposure alone may not lead to de-
velopment of allergic disease. The results will guide use of
comprehensive environmental intervention measures to achieve re-
duction in allergen exposure.
Further studies are needed to confirm if quantifying the level of ex-
posure to relevant allergen can guide immunotherapy and also if pri-
mary prevention of allergy is possible by reducing exposure to
potentially sensitising agents like HDM in the environment.
A28
Probiotic microorganism Lactobacillus reuteri impact on the
prevalence of allergic asthma in five years old Slovene children
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BACKGROUND
The intestinal microflora is very important for maturation of the host’s
innate and adaptive immune responses. Perinatal probiotics supple-
mentation has been shown to be effective in the primary prevention of
atopic dermatitis. Effect of probiotics on prevention of allergic asthma
is less certain. Many reports suggest that certain probiotic strains have
potent immunomodulatory activity in allergic asthma.
OBJECTIVE
The aim of this study was to evaluate the efficacy of probiotic micro-
organism Lactobacillus reuteri (LR) in the prevention of the develop-
ment and exacerbations of asthma in children.
METHODS
This prospective study included 316 maturely born infants with a
positive history of parental allergy confirmed by allergy testing.
According to the addition of LR in to the child diet, they were di-
vided in group A-201 infants exclusively breastfed for 4-6 months,
and group B-115 infants breastfed with addition of LR from
fourth week of life for 12 weeks. Every child was followed up by
the same paediatrician until five years old. The prevalence of
doctor-diagnosed asthma, frequency and duration of asthma at-
tacks and bronchodilator consumption was observed. Statistical
analysis was performed with SPSS 11.0 using chi-square analysis
with Yates’ correction. P-values less than 0.05 were considered
significant.
RESULTS
At the age of 5 years, the prevalence of asthma tended to be higher
in group A (group A: 15.4%; group B: 8.7%), (P=0.08). Higher fre-
quency of asthma attacks (group A: 8.2; group B: 5.8 attacks/asth-
matic child) and longer duration of asthma attack (group A: 11.4;
group B: 9.3 days/attack) was observed in group A. Consumption of
bronchodilators was also greater in group A (Group A: 12.1; group B:
6.3 prescriptions per asthmatic child).
CONCLUSIONS
Our study confirms that addition of LR to early child’s diet has not
preventive effect in asthma development, but there is some benefi-
cial effect on the course of asthma in children.
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Inhalation of fungal aeroallergens is a substantial risk factor for a
wide range of allergic diseases.
OBJECTIVE
An aeromycological monitoring was performed in an urban megacity,
Kolkata, India, to quantify fungal aerospores and to identify allergenic
components of Aspergillus oryzae, one of the most dominant fungi,
by immunoproteomic analysis.
METHODS
Airborne fungi were biomonitored during two years and fungal spore
calendar was prepared. Spore concentrations were correlated with
different meteorological parameters and hospitalization data. After
skin prick test, allergenic potential of Aspergillus oryzae was tested by
ELISA and Histamine assay. Both extracellular and intracellular pro-
teins were analyzed by immuno-proteomic approach. After one and
two dimensional gel electrophoresis, IgE reactive proteins were de-
tected from 1D and 2D Immunoblot (12% and 15%). For intracellular
proteins, presence of glycoprotein in the allergen profile and the role
of sugar moiety in IgE-binding were assessed by Periodic Acid Schiff’s
staining followed by meta-periodate modification. IgE reactive spots
were identified by MALDI-TOF-TOF. Major allergen was purified par-
tially by anion exchange chromatography.
RESULTS
From biomonitoring, Aspergillus were found to be the most pre-
dominant fungi followed by Cladosporium, Penicillium, etc. Spore
concentrations were greatly influenced by meteorological parame-
ters and were positively associated with hospitalization records.
18 intracellular and 10 extracellular allergens of Aspergillus oryzae
were detected from 2D immunoblot. For intracellular proteins,
three allergens were found having glycol moiety as a major con-
tributor of IgE-epitope by Periodic Acid Schiff’s staining followed
by meta-periodate modification. 67% of Aspergillus oryzae allergic
patients were sensitized to glucan 1, 3-beta-glucosidase A (45.434
kDa) by IgE immunoblot, which was identified as major allergen
by MALDI-TOF-TOF. This major allergen (pI 4.63) was partially
purified by anion exchange chromatography and showed its IgE
reactivity by 1D immunoblot confirming successful partial purifi-
cation of this allergen.
CONCLUSIONS
In the present study, glucan 1, 3-beta-glucosidase A is identified as
major allergen from Aspergillus oryzae, which has been reported for
the first time. Immuno-proteomic identification of all IgE reactive pro-
teins is helpful for proper diagnosis and immunotherapy of atopic
diseases.
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OBJECTIVE
We report real-world healthcare use in privately- or publicly-insured
children with severe or poorly-controlled asthma vs those without
asthma in the United States.
METHODS
In US claims databases (years 2008-2014), we identified privately-
and publicly (Medicaid)-insured children (6-11 years old) with severe
or poorly-controlled asthma (≥2 medical claims for asthma, ≥2 filled
pharmacy claims for any asthma medication per 12 months, and ≥1
filled pharmacy claim for high-dose inhaled corticosteroids or chronic
oral corticosteroids or ≥5 pharmacy claims for short-acting beta-
agonists in 3 consecutive months). We matched (1:1) children with vs
without asthma by demographic characteristic and evaluated general
healthcare use rates per patient-per-year.RESULTS
We matched children with asthma vs without asthma (private:
n=33,108 in the asthma group and the same number in the non-
asthma group; Medicaid: n=29,493 in the asthma group and the
same number in the non-asthma group), followed for a mean of 3.2
(private) and 3.6 years (Medicaid). Privately-insured children with
asthma vs without asthma had the following mean (95% CI) rates of
healthcare use: inpatient admissions (0.09 [0.09-0.10] vs 0.02 [0.01-
0.02]), hospital days (0.35 [0.33-0.38] vs 0.08 0.07-0.10]), ED visits
(0.54 [0.53-0.55] vs 0.22 0.21-0.22]), office visits (7.51 [7.46-7.57] vs
3.27 [3.24-3.29]). Medicaid-insured children with asthma vs without
asthma had the following mean (95% CI): inpatient admissions (0.13
[0.12-0.13] vs 0.03 [0.03-0.03]), hospital days (0.57 [0.53-0.61] vs 0.32
[0.27-0.37]), ED visits (1.03 [1.02-1.05] vs 0.41 [0.41-0.42]), office visits
(7.30 [7.23-7.36] vs 2.85 [2.82-2.88]. All p-values <0.01.
CONCLUSIONS
Children with severe or poorly-controlled asthma use more (>2-fold)
healthcare services than children without asthma. The results are
consistent for privately- and publicly-insured children.
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BACKGROUND
Omalizumab has been reported to reduce exacerbations in school-
age children with moderate or severe persistent asthma.
OBJECTIVE
We aimed to describe the effect of omalizumab treatment on the
likelihood of remaining free of asthma exacerbations and healthcare
resource use.
METHODS
This randomized, double-blind, placebo-controlled, phase III clin-
ical trial (years 2004-2008) enrolled children ≥6 to <12 years old
with allergic asthma and randomized them (2:1) to receive omali-
zumab or placebo. Background inhaled corticosteroid (ICS) dose
remained constant during weeks 1-24; investigators could reduce
ICS doses during weeks 25-52. This post-hoc analysis compared
the percentages of children (omalizumab vs. placebo) free of se-
vere exacerbations (those that required systemic corticosteroids
and had a peak expiratory flow or FEV1 <60% of personal best),
clinically significant exacerbations (worsening symptoms requiring
doubling of baseline ICS dose or systemic corticosteroids), clin-
ician reported exacerbations, and healthcare resource use (hospi-
talizations and outpatient services) during weeks 1-52. P-values
were estimated via a chi square test.
RESULTS
Among patients treated with omalizumab (n=384) or placebo (n=192),
the majority (n=365) had severe persistent asthma. During weeks 1-52,
more omalizumab- than placebo-treated children were free of: severe
exacerbations (88.0% vs. 79.2%, 95% CI: 2.2-15.4%, p=0.005), clinically-
significant exacerbations (52.9% vs 39.6%, 95% CI: 4.8-21.8%, p=0.003),
and any clinician-reported exacerbation (25.3% vs. 13.0%, 95% CI: 5.9-
18.7%, p <0.001).
A higher percentage of omalizumab- than placebo-treated children
remained free of hospital admissions (95.6% vs 90.6%, p=0.024) and
unscheduled doctor visits (71.6% vs 62.5%, p=0.032). The percent-
ages of omalizumab- vs placebo-treated children free of ED visits
were: 94.3% vs 91.7% (p=0.246).
CONCLUSIONS
Omalizumab treatment helps children with moderate-to-severe asthma
be free of severe exacerbations, clinically-significant exacerbations, any
World Allergy Organization Journal 2017, 10(Suppl 2):39 Page 12 of 16clinician-reported exacerbations, hospital admissions and unscheduled
doctor visits.
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BACKGROUND
Forced oscillation technique (FOT) facilitates the quantification of re-
spiratory function in young children. Outcomes from FOT and their
utility in non-Caucasian populations are not well understood.
OBJECTIVE
This community-based study explored the use of the FOT in school-
aged children with and without respiratory problems in the United
Arab Emirates (UAE).
METHODS
Three hundred seventy-one Emirati children were recruited from pri-
mary schools and the pediatric respiratory clinic at Tawam Hospital.
Forced oscillation measurements were successful in 351 (95%) chil-
dren, aged three to 12 years. Standardized respiratory history was
available in 330 children (109 with and 221 without respiratory prob-
lems) using a modified global asthma network questionnaire.
RESULTS
Logistic regression model that included weight, height, age and gen-
der, showed only height had significant prediction of FOT values
(p<0.001). Prediction equations for resistance (Rrs), reactance (Xrs)
and area under the curve (AX) were generated based on height, e.g.,
Rrs at 5 hertz (Rrs5) = 20.67 + (-0.10 × height), R2=0.38. Using the
prediction equation derived from the children without respiratory
symptoms Z-scores were calculated. There was statistically significant
difference in Z-score at Rrs5 between children with and without re-
spiratory symptoms (p<0.05, independent sample t-test).
CONCLUSIONS
FOT measurements were feasible in Emirati school-children. The pro-
cedure was brief and well perceived by the children, families, and
school staff. The results identified some children with respiratory
symptoms and high airway resistance.
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BACKGROUND
Challenge test (CT) is the gold-standard for the diagnosis with food
allergy. Its implementation involves a high consumption of time and
resources and implies the risk of severe adverse reactions appa-
reance. Currently, there is not a diagnostic tool able to perform an
early detection of the allergic reactions, thus reducing the length of
the challenge test and decreasing the onset of severe allergic reac-
tions. Heart rate variability has been used for help to the diagnosis of
several illnesses. It has been recently used for the detection of aller-
gic reactions. We explore the use of a heart rate variability monitor-
ing device to detect in real time the allergic reactions in patients
undergoing a CT.
METHODS
Patients with suspected food allergy that, following the normal diag-
nostic protocol, were undergoing a CT and whose parents or tutorsagreed to participate. A remote monitoring device called Shimmer
was placed from10 minutes before the start of the test until Its com-
pletion. Increasing doses of the food were administered at 30 mi-
nutes interval untill the end of the test or until the onset of allergic
symptoms. Heart rate variability was analysed by the proposed algo-
rithm, and Its results were compared to the CT results.
RESULTS
Sixty six patients (52 children and 14 adults) were studied: 30 fe-
males, 36 males, mean age 5,6 years (IQR 2-11 y). Foods tested in-
cluded milk (20), egg (18), fish (13), fruits (6) and others (9). The food
CT was positive in fourteen of them (21%). The algorithm detection
showed a positive result in 41 patients and a negative one in 25. Its
sensitivity and specificity were 93% and 46% respectively. The global
negative predictive value was 96%. The detection was a mean of 64
minutes before the onset of symptoms.
CONCLUSIONS
The use of a heart rate variability device with a mathematic algo-
rithm can be a useful tool to increase safety in food allergy diagnosis.
Further studies are needed.
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BACKGROUND
Asthma is a common chronic respiratory disease in childhood and
adolescence and it is associated with reduced quality of life, hospital-
izations and rarely deaths.
OBJECTIVE
The objective of the study was to evaluate out-of-hospital asthma
deaths in Brazil, from 1996 to 2014, occurring in the age group be-
tween zero and nineteen years old.
METHODS
This is an ecological study, based on the database collected in
DATASUS, CGIAE (General Coordination of Information and Ana-
lysis Epidemiologic). The identification of deaths was conducted
by the ICD (International Classification of Diseases and Related
Health Problems), 10th revision, J-45 (asthma) and J-46 (status
asthmaticus) as root causes in Brazil. The variable studied was
the place of death, considering wether it occurred in a hospital
or out-of-hospital (another health establishment, residence, public
road, others, ignored).
RESULTS
From January 1996 to December 2014, there were 4872 asthma
deaths in Brazil, in children and adolescents between zero and 19
years. Of these deaths 3815 (78,5%) occurred in hospital e 21,5%
out-of-hospital. Considering the age, in the group under one year,
17,3%, between 1 to 4 years: 20,9%, from 5 to 9 years: 22,3%, in
group 10 to 19 years, 27,2%, ocurred out-of-hospital (another health
establishment, residence, public road, others, ignored). The difference
was statistically significant in the group of 10 to 19 years (p < 0.005).
CONCLUSIONS
It would be desirable for all cases of asthma attacks to occur in a
hospital environment and with broad access to tertiary resources.
Out-of-hospital asthma deaths were significantly higher among ado-
lescents. Most asthma deaths are avoidable. Factors related to access
to health services for asthma care, availability of medications and ad-
herence to treatment, association with others clinical diseases, and
sociodemographic issues may increase the risk of death from the dis-
ease. There are well-established strategies for reducing morbidity
and mortality from asthma, that includes the regular use of prevent-
ive medications, especially inhaled corticosteroids, education of the
patient and his family and portability of a plan of action for the early
treatment of exacerbations. The main objective of studies about
asthma mortality is the orientation and the elaboration of public
World Allergy Organization Journal 2017, 10(Suppl 2):39 Page 13 of 16health policies, strategies and priorities for prevention and treatment
of the disease.
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BACKGROUND
Ragweed pollen (Ambrosia artemisiifolia) represents approximately
20% out of the total pollen concentration in the Western part of
Romania, and is highly allergenic, inducing severe allergic symptoms.
Few studies have focused on pollen exposure and allergic manifesta-
tions in children.
OBJECTIVE
The study aims to evaluate the association between higher ambient
levels of ragweed pollen in the first 2-4 years of life and risk of
sensitization and development of allergic rhinitis in children at age
of 12, in comparison with adult subjects.
METHODS
Using the patient cohort with allergic respiratory symptoms (n =
10,883) evaluated between 2008 and 2016 in the Allergy Outpatient
Clinic Timisoara, we examined allergic sensitization (SPT > 3 mm to
at least one of birch, rye grass, ragweed, house dust-mite, dog and
cat dander) by age 2 and the development of allergic rhino-
conjunctivitis or/and asthma at age 12, in comparison with adult
subjects.
RESULTS
Most of adult patients (63.5%) were polysensitized to both indoor
and outdoor allergens, out of which, 60% were sensitized to rag-
weed. In monosensitized adult patients, ragweed allergy was present
in 42%, more than to any other type of airborne allergen, followed
by house dust mite (38.5%). All patients with a disease history longer
than 10 years had developed allergic asthma. For the period 2015-
2016 there were 6 cases of children between 1.5 and 4 years of age,
and a total of 57 children under 12 years of age with documented
ragweed allergic rhinoconjunctivitis.
CONCLUSIONS
Exposure to high concentrations of ragweed pollen in infancy ap-
pears to increase the risk of rhinoconjunctivitis in children under 4
years. These results support the hypothesis that high level of rag-
weed pollen can induce sensitization and the development of aller-
gic symptoms early in life, and progression to asthma in adulthood,
even if the period of exposure is less than 3 months per year.
A36
Allergy unit in oncology institute – First national experience about
the first 600 desensitizations to chemotherapeutics and
monoclonal antibodies
Enrique Martí Guadaño1, Carolina Escobar Bolaños1, Natalia Martí José1,
Pol Pau Casanovas2, Gemma Biarnés Rib2, Mariana Castells3
1Allergy Unit, Institut Català d’Oncològia, Barcelona, Spain; 2UDAM
Allergy Unit, Barcelona, Spain; 3Desensitization Unit, Brigham and
Women’s Hospital, Boston, MA, USA
Correspondence: Enrique Martí Guadaño (udam93@hotmail.com)
World Allergy Organization Journal 2017, 10(Suppl 2):A36
BACKGROUND
There is an increase in malignant proliferative diseases as well as in
allergic pathology. The Institut Català d’Oncologia, (ICO), covers 4 mil-
lion inhabitants in the Barcelona area, publishes 4 per thousand of
adverse reactions to chemotherapy, mediated or not by allergic
mechanisms, and, in most cases, leaving the first therapeutic lines,
for second one, safer, but less effective and undoubtedly higher dir-
ect costs.OBJECTIVE
Our aim is to reverse that process, to get the opportunity to keep
those patients with the best of possible medications.
METHODS
Two part-time allergists, one nurse specialized in drug allergy, one
pharmaceutical, under the coordination of one Head of Unit. First visit,
skin tests, risk stratification and desensitization decision, place and
number of steps. The desensitization protocols used are from Brigham
and Women’s Hospital of Boston, world pioneers of this technique. In
cases of new drugs, this hospital and its Desensitization Unit led by Pro-
fessor Mariana Castells was consulted for her experience.
RESULTS
185 patients, with different types and stages of cancer, predomin-
antly ovary, breast and colon; 601 cycles of desensitization, mainly to
Platins and taxanes; 98% of successes (reaching final dose prescribed
by oncologist) 70% were 12-step cycles and 25% of 16; All in Day
Hospital, except 2 in Intensive Care.
CONCLUSIONS
The results show that a Chemotherapy Drug Desensitization Unit,
managed by allergists, increases the population’s survival expecta-
tions with cancer and allergy to necessary drugs, being able to main-
tain the first therapeutic line, recommended by the international
guidelines, and that of another form, they are confronted with sec-
ond choices, safer perhaps, but clearly less effective.
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BACKGROUND
Food can be a highly significant trigger for IgE mediated anaphylaxis
in children. Bearing in mind the limitation of epidemiologic chal-
lenges in determining the burden of food-induced anaphylaxis (FIA),
it is estimated during recent years that the incidence of FIA in chil-
dren (likely affects 8%) is increasing as well as in adults (nearly 5%),
with growing evidence of an increase in prevalence: Hospitals admis-
sions for FIA have more than doubled in the last decade.
METHODS
15 year-old-girl feeling stomach pain, facial swelling, onset of acute
bronchospasm, reduced blood pressure and syncope, within an hour
at school, after having for breakfast milk with a new brand of a nut-
cereal bar at home. Her teachers performed 15 minutes of insuffla-
tion without cardiac massage until the emergency services arrived.
They performed 8 minutes of basic CPR, 10 minutes of advanced
CPR: Orotracheal intubation, intratracheal and intravenous Adren-
aline, intratracheal Salbutamol and Magnesium sulfate. She recovered
sinus rhythm. (Total arrest time: 33 minutes). On arrival at pediatric
ICU: pH 6.9, pCO2 120mmHg, lactic acid 33mmol, 98% O2 + FiO2
100%, heart rate 118, T 32.4 C, blood pressure 89/ 32mmHg.
RESULTS
History of atopic disease, uncontrolled asthma, food allergy to shell-
fish, egg, peanut, nut and grass allergy was known, but the patient
did not check-up with the allergy specialist. Outcome: Mechanical
ventilation was needed, the patient remained in unreactive coma
with tendency to hypotension, managed with dopamine. Further
studies confirmed allergy history, respiratory deterioration, shock and
irreversible end of brain activity after 6 days in intensive pediatric
care unit at hospital, where she finally died. Organ donor.
CONCLUSIONS
Intramuscular epinephrine injection is a safe and effective treatment of
anaphylaxis in children. A study of anaphylaxis fatalities found that 23%
of those who died did not receive epinephrine until cardiac arrest.
Children with systemic allergic reactions should carry epinephrine
auto injectors at all times, specially those who have shown severe
outcomes and should certainly have one with them at school. In
order for epinephrine auto injectors to be effective, children, their
families and caregivers must be carefully counselled and educated
World Allergy Organization Journal 2017, 10(Suppl 2):39 Page 14 of 16on how to properly use the devices and when to use them. Instruc-
tions on allergen avoidance are key in managing allergies.
CONSENT TO PUBLISH
Consent to publish was obtained from the parents of the patients in
this study.
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BACKGROUND
Eosinophilic oesophagitis (EoE) is a disorder characterized by
oesophageal dysfunction and, histologically, by eosinophilic inflam-
mation. Although restrictive diets are often effective, choosing the
foods to be eliminated is difficult. Sensitization tests with molecular
analysis could allow better-targeted dietary restrictions.
OBJECTIVE
This is a retrospective analysis of patients diagnosed with EoE at our
“Pediatric Digestive Surgery-Allergy joint putpatient clinic” over the period
2015-2016, in order to describe their allergenic sensitization.
METHODS
All children who received a histological diagnosis of EoE over the
period 1st January 2015 - 30th November 2016 were tested by a stand-
ard series of Skin Prick Test (SPT) for aeroallergens and food allergens
in accordance with the EAACI guidelines. Specific IgE were performed
when clinically indicated. The available data on specific IgE to LTPs
from peach (Pru p 3), hazelnut (Cor a 8), peanut (Ara h9), apple (Mal d3)
were also analysed. Levels of IgE>0.35 kU/L were considered positive.
RESULTS
Forty-five patients (24 Male; median age 8.53 years; range 1.78-17.12
years; 37 /45 not responder to proton pump inhibitor) were retro-
spectively analyzed. Four of 37 (10.8%) resulted completely negative
for food or aeroallergens.
Twenty subjects (54.1%) showed at least one positivity at SPT for aero-
allergens and 13 (35.1%) at least one positivityto foods. Twenty-one out
of 37 patients (56.7%) performed specific IgE evaluation: 19/21 returned
positive for any aeroallergen and 17/21 for any food. Combining the re-
sults of SPT and specific IgE, 12/37 and 15/37 patients were negative
for aeroallergens and foods respectively; 9 and 12 were positive for 0-2
aeroallergens or foods respectively and 16 and 10 subjects were posi-
tive for more than 2 aeroallergens or foods respectively. Fifteen pa-
tients perform LTPs analysis: 10/15 (66.7%) resulted negative for all
tested LTPs, while 3 subjects showed positivity only for Pru p3 and 2
patients for Pru p3, Cor a 8 and Ara h9.
CONCLUSIONS
In our EoE caseload, the frequency of sensitization to respiratory al-
lergens is similar to that of food allergens. LTP-syndrome was found
in 30% of the tested patients. These data suggest that all EoE pa-
tients should be evaluated from an allergological point of view. In
this context, many efforts of cooperation between paediatric gastro-
enterologist and allergist should be provided.
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Probiotic’s ability to alter the intestinal microbiotic niches is
controversial.
OBJECTIVE
We aim to investigate the ability of a probiotic preparation to modu-
late the composition of the intestinal microbiota of food-allergic
infants.
METHODS
Infants aged 10-14 months with clinical history and IgE sensitization
to egg and/or milk underwent diagnostic DBPCFC. Those confirmed
allergic (group I) were randomly assigned to receive Bifidobacterium
longum BB534 (BL), Bifidobacterium breve M-16V (BB) and Bifidobac-
terium infantis M-63 (Tribif®, Valeas, Milano) for 30 days. Faecal sam-
ples at 0, 7, 15, 30, 60 and 90 days from the start of administration of
Tribif® were evaluated, after DNA extraction, by quantitative real-time
PCR (qPCR). We used specific BB534 (BL) and M-16V (BB) primers ob-
tained after amplification of fragments of 118 and 109 bp. Two con-
trol groups of egg and milk-IgE-positive infants with negative food
challenge (group II) and IgE-negative healthy infants (group III) were
evaluated for BL and BB in basal conditions.
RESULTS
Of 25 infants (15M, 10F, mean age 13.28±2.13 months), 9 (6M, 3F)
were DBPCFC-positive to egg (5) or milk (4). Group II was composed
by 6 infants (3M, 3F), group III by 6M and 4F. BL was found in the
microflora of all children irrespective of their atopic status; BB was
absent in 5/25, all in group I. The peak concentrations of BL were
reached at 7 days in 5/9, 15 days in 3/9, and 30 days in 1/9. After dis-
continuation, BL concentration felt to basal levels. When two of these
children had to take antibiotics for intercurrent pathologies, the BL
concentration dramatically falls. For BB, the peak was reached at 7
days in 2/9, 15 days in 3/9, 30 days in 3/9. BB never colonized the pa-
tient who did not show peaks. The two patients who received an
antibiotic in the first and second week of administration of Tribif® for
intercurrent diseases had BB peaks at 30 days.
CONCLUSIONS
BL and BB are part of the normal bacterial microflora, and the ab-
sence of BB colonization may be associated with atopic status. Des-
pite the considerable individual variability in kinetics of the
Bifidobacteria, the detection of a significant concentration between 0
and 30 days in 8/9 cases with for BL and in 6/9 with BB suggests that
the probiotic administered do reach and colonize the intestinal tract.
As the effect seems higher in cases in which the baseline concentra-
tion is low, Tribif® seems able to restore the ecological niche of Bifido-
bacterium in children where it is depleted.
A40
Hypoallergencity and tolerance of a new amino acid-based
formula in children with cow’s milk allergy
Lamia Dahdah1, Vincenzo Fierro1, Claudia Banzato2, Luís Angel
Echeverría Zudaire3, Ana María Plaza4, Montserrat Bosque García5, Marcel
Íbero6, Oscar Mazzina1
1Division of Allergy, University Department of Pediatrics, Pediatric
Hospital Bambino Gesù, Rome, Vatican City Italy; 2Department of Life
and Reproduction Sciences, Section of Pediatrics, University of Verona,
Verona, Italy; 3Pediatric Allergy Unit, Severo Ochoa Universitary Hospital,
Leganés, Spain; 4Pediatric Allergy and Clinical Immunology Department,
Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain;
5Division of Pneumology, Hospital Parc Taulí, Autonomous University of
Barcelona, Barcelona, Spain; 6Allergy Unit, Hospital de Terrassa,
Barcelona, Spain
Correspondence: Vincenzo Fierro (vincenzo.fierro@opbg.net)
World Allergy Organization Journal 2017, 10(Suppl 2):A40
BACKGROUND
According to the American Academy of Pediatrics (AAP), a hypoaller-
genic formula must demonstrate with 95% confidence that 90% of
infants with confirmed cow’s milk allergy (CMA) will not react with
defined symptoms under clinical trial conditions.
OBJECTIVE
A prospective, double-blind placebo controlled, multi-country study
was conducted to assess the hypoallergenicity of a new amino acid-
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commercially available hypoallergenic infant formula was used as a
control. Primary aim was the incidence of immediate and/or delayed
allergic reactions to double blind placebo controlled food challenge
(DBPCFC). Secondary aim, the short-term effects on growth and toler-
ability of the new AAF were assessed.
METHODS
41 subjects were enrolled and 30 subjects completed the study
as per protocol. Patients were recruited after being clinical
symptoms-free for one week (or with controlled stable symptoms)
and not showing allergic symptoms after the DBPCFC with the
new AAF. Subjects consumed at least 250 ml per day during two
weeks of study period. Data on anthropometrics, allergic reac-
tions, immunology and health status in general (Symptoms-based
clinical score of Vandenplas, SBS) were collected and parents re-
corded product intake and observed subjective symptoms on the
diary.
RESULTS
There were no serious or non-serious adverse events related to any
of the two AAF reported in this study. Statistically significant positive
difference in weight (p= 0.0019) and height (p < 0.001) were found
after 2 weeks of follow-up. All secondary outcomes in gastro-
intestinal, respiratory and dermatological tolerability on SBS de-
creased but without a statistical difference.
CONCLUSIONS
The new formula meets the AAP criteria for hypoallergenicity and
the results suggest good tolerability. Patients’ growth seems not hin-
dered by the new formula.
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BACKGROUND
A fraction of food-allergic patients are sensitive to minute
amounts of foods. They must correctly read the food labels,
reporting allergenic ingredients according to local legislation
worldwide. In response to these regulations, some industries have
also spontaneously added some precautionary allergen labelling
(PAL), indicating the possible contamination of foods by aller-
genic traces.
OBJECTIVE
To evaluate the tolerance to milk and egg-free biscuits among chil-
dren with severe milk and egg allergy; to explore the possibility that
proteomic methods can be used to avoid PAL.
METHODS
A prospective, double-blind placebo, mono-centric controlled study
was conducted to assess the hypoallergenicity of “Magretti-Galbusera
Frolini con orzo e mais” (MGF) in children with cow’s milk and hen’s
egg anaphylaxis. The primary outcome was assessed by double blind
placebo controlled food challenge (DBPCFC) with MGF. The presence
of milk and/or egg allergen traces in MGF was assessed by nanoLC-
MS/MS mass spectrometry. The binding of patients’ serum with MGF
proteins was assessed at Western Blot.
RESULTS
We preliminarily report on 25 enrolled children (target per proto-
col: 29). None of them reacted to MGFs. Patient’s sera (17 tested
until now) showed no reactivity with proteins extracted from
MGFs. The initial proteomic analysis was negative for egg and
milk proteins in MGFs. Unique signature peptides specific to
cow’s milk and hen’s egg are being analyzed, and a quantitative
analytical method on latest generation triple quadrupole mass
spectrometer (QTrap 6550+, Sciex) is being developed to assess
allergens at very low concentration (below 10 ppm).CONCLUSIONS
MGFs seem to meet the AAP criteria for hypoallergenicity. Proteomic
techniques may be useful to evaluate the exact amount of protein
within the food. Should their sensitivity be pushed up to dose amount
of proteins lower than those that can theoretically determine an allergic
reaction, they could help in avoiding unnecessary PAL.
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BACKGROUND
Therapies for food allergy include elimination diets, Oral Immuno-
Therapy (OIT), and the administration of biologics. Omalizumab has
been licensed for use in severe allergic asthma and chronic urticaria
and its dosing was based on body weight and baseline serum IgE
concentration. Omalizumab is currently evaluated as support for OIT.
OBJECTIVE
To evaluate the effect of Omalizumab on food allergy in children
with severe asthma.
METHODS
Children with severe asthma and anaphylactic reactions to two or more
foods were prospectively enrolled between August 2014 and August
2016. All patients were required to have a baseline IgE between 30 and
1500 IU/ml and body weight not more than 150 kg. Hypersensitivity
was confirmed and the threshold dose for each food established by a
double-blind, placebo-controlled oral food challenge (DBPCFC) at
screening. Patients were assigned to receive either Omalizumab (150,
300, or 450 mg) every two-four weeks. The patients underwent a fur-
ther oral food challenge to previously positive foods within two to four
weeks after the fourth dose.
RESULTS
We enrolled 6 patients (median age 6.98 years; age range 6.98-20.8; 5
males). The mean serum total IgE value was 665 ku/L, and their asthma
was out of control despite treatment as per GINA III or IV step. At enroll-
ment, five patients showed allergy for cow milk, four for egg and three
for wheat. After treatment, 5/6 patients developed full tolerance to at
least one specific food. One patient showed tolerance to baked egg
after 5 doses of Omalizumab and to egg after 16 doses; one child de-
veloped tolerance to cow milk after 8 doses; one patient developed tol-
erance to baked cow milk after 8 doses and other two patients showed
tolerance to wheat after 4 and 12 doses respectively. The only patient
who did not reach full tolerance showed an 85% increase of tolerance
to milk (92 mL vs. 14) and an 82% increase of tolerance to egg (25 g vs.
4.4) at DBPCFC. Omalizumab was well tolerated in all children.
CONCLUSIONS
A trial of Omalizumab significantly and substantially increased the
threshold of sensitivity to foods on oral food challenge. This effect
should translate into protection against most unintended ingestions
of food allergens.
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BACKGROUND
Food Protein Enterocolitis Syndrome (FPIES) is a non-IgE food allergy
with an unknown prevalence and pathophysiology. Acute FPIES
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repetitive emesis, pallor, lethargy, and water or bloody diarrhea pro-
gressing to dehydration and a possible hypovolemic shock.
METHODS
A retrospective descriptive single-center study was conducted. Sub-
jects included in this study were children with acute FPIES to cow’s
milk who entered in our institutional follow-up protocol between
January 2013 and February 2017.
RESULTS
Among the 21 patients (twelve boys and nine girls), five (23,8%) were
affected by Down syndrome. All patients experienced acute FPIES reac-
tion after the ingestion of cow’s milk and four with beef meet (one had
a Down phenotype and showed a mild reaction). The average time
from ingestion to symptom onset was 120 minutes. The clinical mani-
festations ranged from mild-moderate (repetitive vomiting with less
than three episodes of emesis and pallor) to severe (repetitive vomiting
with more than three episodes of emesis, pallor, lethargy, dehydration)
or very severe (severe symptoms plus cyanotic appearance and water/
bloody diarrhea). Patients with Down syndrome experienced acute
FPIES reactions with a severity degree comparable to that reported in
other patients. Twelve children were hospitalized, five of them several
times. The delay between first reaction and diagnosis was 6.5 months
on average. Allergy tests (skin prick test and serum milk protein
fractions-specific IgE) were negative in all cases. One patient changed
from an acute FPIES to an IgE-mediated phenotype over time.
CONCLUSIONS
To our knowledge, this is the first time that the presence of FPIES reac-
tions in patients with Down syndrome is reported. It is interesting to note
that patients with Down phenotype show peculiarly FPIES reactions to
cow’s milk proteins accounting for nearly a quarter of the present series.
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BACKGROUND
Allergic rhinitis is a common inflammatory condition of the upper air-
ways. Antioxidant supplements have proven beneficial in a number
of immune-mediated and allergic diseases.
PURPOSE
The current systematic review seeks to synthesize the results of avail-
able randomized trials.
METHODS
Study Design: Systematic review and meta-analysis. MEDLINE,
EMBASE, Cochrane Library, Clinical-Trials.gov, and Scopus databases
were reviewed through January 2016 for randomized controlled trials
on defined inclusion criteria.
Study selection: Randomized, controlled trials of various antioxidant
supplements that used for the treatment of allergic rhinitis with
enough data for meta-analysis.
Data extraction: Two reviewers independently extracted data and
assessed study quality. The effect of antioxidant supplements on Rhin-
itis Quality of Life (RQLQ) scores, Rhinitis Total Symptom Scores (RTSS),
as well as total and antigen-specific serum IgE levels were evaluated by
meta-analysis. The risk of bias and overall strength of evidence of stud-
ies were assessed.
RESULTS
A total of 68 studies were identified, including 8 double-blind random-
ized controlled trials studies. Various antioxidant supplements, study
populations, and outcome measures were utilized in individual trials.
Four studies showed a significant clinical benefit from the use of anti-
oxidant supplements in at least one outcome measure when compared
to placebo. Among the trials eligible for meta-analysis, the use of anti-
oxidant supplements resulted in significant improvement in RQLQ
scores compared to placebo [standard mean difference (SMD) -1.22; p
= 0.05] and total IgE levels [SMD 0.01; p = 0.04], while there was a trend
toward a reduction in antigen-specific IgE [SMD 0.18; p = 0.07] in the
placebo group compared to antioxidant supplements.
CONCLUSIONS
Antioxidant supplements may be beneficial in improving symp-
toms and quality of life in patients with allergic rhinitis, however,
current evidence remains limited due to study heterogeneity and
variable outcome measures. Additional high-quality studies are
needed to establish appropriate recommendations.•  We accept pre-submission inquiries 
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